Osteoporosis and Sarcopenia最新文献_第6页

Romosozumab not only enhanced bone mineral density but also improve back pain and life quality

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.034

Chung-Hwan Chen , Sung-Yen Lin , Tien-Ching Lee , Cheng-Jung Ho , Jhong-You Li

引用次数: 0

Application of deep learning algorithm to detect and visualize vertebral fractures on plain radiographs

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.009

Hsuan-Yu Chen , Christina Soong , Feng-Huei Lin , Tsung-Han Yang , Ding-Cheng Chan , Chih-Hao Chang , Rong-Sen Yang

引用次数: 0

Musculoskeletal and neurocognitive clinical significance of adult hypophosphatasia 成人低磷酸盐症的肌肉骨骼和神经认知临床意义

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.12.003

Se-Min Kim, Funda Korkmaz, Steve Sims, Vitaly Ryu, Tony Yuen, Mone Zaidi

{"title":"Musculoskeletal and neurocognitive clinical significance of adult hypophosphatasia","authors":"Se-Min Kim, Funda Korkmaz, Steve Sims, Vitaly Ryu, Tony Yuen, Mone Zaidi","doi":"10.1016/j.afos.2023.12.003","DOIUrl":"10.1016/j.afos.2023.12.003","url":null,"abstract":"<div><div>Hypophosphatasia (HPP), also called Rathbun disease, is a rare genetic disorder that is caused by the loss-of-function mutation in the <em>ALPL</em> gene encoding tissue non-specific alkaline phosphatase. Doctor Rathbun first described the case of a 3-week-old infant who presented with severe osteopenia, rickets, and multiple radiographic fractures, and died shortly after of epileptic seizure and respiratory distress. The term “hypophosphatasia” was coined as the patients’ alkaline phosphatase levels were significantly low. Since then, our understanding of HPP has evolved, and now we appreciate causative genetic mutation and the broad spectrum of clinical presentation depending on the age of onset, severity, and skeletal involvement: perinatal, infantile, childhood, adult and odontohypophosphatasia. The new development of enzyme replacement with asfostase alfa has saved the lives of severe form of hypophosphatasia. However, it is still unclear and remains challenging how to manage adult HPP that often presents with mild and non-specific symptoms such as muscle pain, joint stiffness, fatigue, anxiety, or low bone mass, which are common in the general population and not necessarily attributed to HPP. In this review, we will present 3 unique cases of adult HPP and discuss the pathophysiology, clinical presentation particularly neuromuscular and neurocognitive symptoms and management of adult HPP.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"9 4","pages":"Pages 115-120"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139015335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats 特立帕肽和依替卡西肽可改善慢性肾病模型大鼠的骨骼、纤维化和脂肪参数。

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.002

Shun Igarashi , Yuji Kasukawa , Koji Nozaka , Hiroyuki Tsuchie , Kazunobu Abe , Hikaru Saito , Ryo Shoji , Fumihito Kasama , Shuntaro Harata , Kento Okamoto , Keita Oya , Naohisa Miyakoshi

{"title":"Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats","authors":"Shun Igarashi , Yuji Kasukawa , Koji Nozaka , Hiroyuki Tsuchie , Kazunobu Abe , Hikaru Saito , Ryo Shoji , Fumihito Kasama , Shuntaro Harata , Kento Okamoto , Keita Oya , Naohisa Miyakoshi","doi":"10.1016/j.afos.2023.11.002","DOIUrl":"10.1016/j.afos.2023.11.002","url":null,"abstract":"<div><h3>Objectives</h3><div>Chronic kidney disease (CKD) complicated by secondary hyperparathyroidism (SHPT) is associated with an increased risk of fragility fractures. Etelcalcetide (EC) is a treatment for SHPT that reduces serum parathyroid hormone (PTH) levels. However, the effects of combined treatment with osteoporosis drugs such as teriparatide (TPTD) remain unclear. This study investigates the combined effects of EC and TPTD on bone in CKD model rats.</div></div><div><h3>Methods</h3><div>The CKD model was established in 8-week-old male Wistar rats by feeding them a 0.75% adenine diet for 4 weeks. At 20 weeks of age, the rats were divided into 4 groups (N = 9–10 in each group): CKD group (vehicle administration), TPTD group (30 μg/kg, 3 times/week), EC group (0.6 mg/kg, daily), and Comb group (TPTD and EC combined). EC was injected for 12 weeks starting at 20 weeks of age, and TPTD was injected for 8 weeks starting at 24 weeks of age. After treatment, the followings were evaluated: bone mineral density, bone strength, biochemical tests, bone and fat histomorphometry, and micro-computed tomography.</div></div><div><h3>Results</h3><div>In CKD model rats, the combination of EC and TPTD was more effective in increasing cortical bone thickness and bone strength and inhibiting porosity. In addition, the combined treatment decreased bone marrow adiposity and fibrosis, and it increased bone mass and improved bone microstructure in trabecular bone.</div></div><div><h3>Conclusions</h3><div>With the observed benefits such as improved bone mass, bone strength, structural properties, and bone marrow adiposity, combination therapy may be a potential way to improve bone fragility in CKD.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"9 4","pages":"Pages 121-130"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139907270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resistance training and nutritional support improve sarcopenia with favorable changes in metabolomics and lipidomics

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.030

Wei-Hsiang Hsu , San-Yuan Wang , Yen-Ming Chao , Ke-Vin Chang , Der-Sheng Han , Yun-Lian Lin

引用次数: 0

The effects of integrated osteoporosis education on osteoporosis knowledge, attitude, behavior and quality of life among middle-aged and elderly osteoporosis patients

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.028

I-Chin Huang , Chih-Lung Lin , Hsiu-Hung Wang

引用次数: 0

Comparison of refracture and mortality of forearm fracture in middle-aged and elderly people with or without combination of traditional Chinese and western medicine

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.041

Ching-Feng Cho , Chia-Chun Li , Ta-Wei Tai , Ching-Ju Chiu , Chih-Hsing Wu

引用次数: 0

Associations between a high ‘calcium, potassium and protein’ dietary pattern, osteopenia and osteoporosis in older adults in Malaysia

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.017

Vaidehi Ulaganathan , Geeta Appannah , Subashini C. Thambiah , Swan Sim Yeap , Intan Nureslyna Samsudin , Salmiah Md-Said , Siti Yazmin Zahari-Sham , Fen Lee Hew , Subapriya Suppiah

引用次数: 0

A hand surgery nurse specialist clinic improves rate of osteoporosis screening and education

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.019

SzeHuey Chan , F. Johari

引用次数: 0

Effects of Teriparatide versus Vertebroplasty on pain control and radiographic outcomes after osteoporotic vertebral compression fracture

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.033

Chi-Chien Niu , Po-An Chen , Ping-Yeh Chiu , Fu-Cheng Kao , Ming-Kai Hsieh , Tsung-Ting Tsai , Po-Liang Lai , Tsai-Sheng Fu

引用次数: 0